Boston Scientific told the US Securities and Exchange Commission on 8 September that a cyberattack is likely to have a material impact on its results for the third quarter and the full year 2026 [1].
The company says it is now unlikely to meet the sales-growth and adjusted earnings guidance it gave on 29 July [1].
It identified the incident on 25 August. Unauthorised activity caused a network outage that cut access to operating systems and business applications, affecting its ability to manufacture, process and ship orders [1].
What it covers
The company's operations worldwide. By its filing on 8 September, its main distribution centres were shipping at or above normal levels, its sterilisation sites were working, and manufacturing had resumed at most facilities [1].
It had found no evidence of continuing unauthorised access, and says the timeline for a full recovery is uncertain [1].
It expects to recover some of the lost revenue as it clears backlogs, and will update its outlook on 28 October with its third-quarter results [1].
What it does not tell you
Who was behind the attack, or whether data about patients, customers or staff was taken. The filing does not say, and the investigation is continuing [1].
How much revenue was lost. The filing gives no figure [1].
Comments